Springer Tumors of the Central Nervous System, Volume 4: Brain Tumors (Part 2)

Product Description This volume focuses on the diagnosis, therapy, and prognosis of brain tumors. Insights on the understanding of molecular pathways involved in tumor biology are explained, which could potentially lead to the development of effective drugs. Review From the reviews:“The purpose is to address the main achievements in the neuroscience of tumors of the central nervous system. This volume deals with intracranial tumors. Neurosurgeons, neurologists, neuroradiologists, neuropathologists, molecular biologists, radiation therapists, and radiologists are the main audience. … The illustrations, text, and presentation are superb. Excellent in its presentation, content, and up-to-date information, this book deserves a spot in academic libraries serving neurosurgeons and neurologists.” (Celso Agner, Doody’s Review Service, March, 2012) From the Back Cover This volume mainly contains information on the diagnosis, therapy, and prognosis of brain tumors. Insights on the understanding of molecular pathways involved in tumor biology are explained, which should lead to the development of effective drugs. Information on pathways (e.g., hedgehog) facilitates targeted therapies in cancer. Tumor models are also presented, which utilize expression data, pathway sensitivity, and genetic abnormalities, representing targets in cancer. For example, rat model of malignant brain tumors using implantation of doxorubicin with drug eluting beads for delivery is explained. The future of pathway-driven therapies for tumors is summarized. The importance of personalizing cancer care is emphasized. The need for supportive measures for survivors of brain cancer is pointed out, so is the quality of life monitoring. The need of rehabilitation therapy for patients with primary and metastatic brain tumors is also emphasized. Role of MicroRNA in distinguishing primary tumors from metastatic primary tumors is discussed. Advantages and limitations of chemotherapy (e.g., temozolomide and doxorubicin) are discussed. The complexity of tumor to tumor transfer is explained; examples discussed are: brain metastases from breast cancer and brain metastases fro non-small cell lung carcinoma. Identification and characterization of biomarkers, including those for metastatic brain tumors, are presented. Genomic analysis for identifying clinically relevant subtypes of glioblastoma is included. A large number of imaging modalities are detailed to study progression and invasion of gliomas.